Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axis-Shield, the international in-vitro diagnostics company, has completed the development and manufacturing of a new assay for homocysteine to run on Abbott's Architect family of automated immunoassay analysers.
Subscribe to our email newsletter
The test has also been cleared for US marketing by the FDA under the 510(k) procedure. The forthcoming global launch of this new test will now incorporate the US, following the regulatory clearance received from the FDA.
Ian Gilham, CEO of Axis-Shield, said: “We are pleased to be launching this proprietary assay on Abbott’s flagship Architect system. The importance of measuring homocysteine blood levels on a regular basis is now more widely recognised and the availability of this marker on Architect should help to develop the market and increase the frequency of testing.”